Cardiovascular Risk Beyond Low-Density Lipoprotein Cholesterol.

[1]  L. Räber,et al.  Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials , 2018, European heart journal.

[2]  R. Collins,et al.  Lipids, Lipoproteins, and Metabolites and Risk of Myocardial Infarction and Stroke , 2018, Journal of the American College of Cardiology.

[3]  Lukas Reiter,et al.  Plasma Proteomics for Epidemiology: Increasing Throughput With Standard-Flow Rates , 2017, Circulation. Cardiovascular genetics.

[4]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[5]  B. Nordestgaard.  A Test in Context: Lipid Profile, Fasting Versus Nonfasting. , 2017, Journal of the American College of Cardiology.

[6]  P. Ponikowski,et al.  Cardiovascular Efficacy and Safety of Bococizumab in High‐Risk Patients , 2017, The New England journal of medicine.

[7]  Xiaoke Yin,et al.  Very-Low-Density Lipoprotein–Associated Apolipoproteins Predict Cardiovascular Events and Are Lowered by Inhibition of APOC-III , 2017, Journal of the American College of Cardiology.

[8]  D. Rader,et al.  Deep Apolipoprotein Proteomics to Uncover Mechanisms of Coronary Disease Risk. , 2017, Journal of the American College of Cardiology.

[9]  R. Gerszten,et al.  The Emerging Role of Metabolomics in the Diagnosis and Prognosis of Cardiovascular Disease. , 2016, Journal of the American College of Cardiology.

[10]  S. Crooke,et al.  Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials , 2016, The Lancet.

[11]  M. Endres,et al.  Statins and risk of poststroke hemorrhagic complications , 2016, Neurology.

[12]  A. Hofman,et al.  Genetic loci for serum lipid fractions and intracerebral hemorrhage. , 2016, Atherosclerosis.

[13]  B. Nordestgaard.  Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights From Epidemiology, Genetics, and Biology. , 2016, Circulation research.

[14]  P. Libby,et al.  Requiem for the 'vulnerable plaque'. , 2015, European heart journal.

[15]  Jennifer G. Robinson,et al.  Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. , 2015, The New England journal of medicine.

[16]  Improve-It Investigators.  Ezetimibe added to statin therapy after acute coronary syndromes , 2015 .

[17]  Jennifer G. Robinson,et al.  Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. , 2015, The New England journal of medicine.

[18]  V. Fuster,et al.  The myth of the "vulnerable plaque": transitioning from a focus on individual lesions to atherosclerotic disease burden for coronary artery disease risk assessment. , 2015, Journal of the American College of Cardiology.

[19]  Pasi Soininen,et al.  Quantitative serum nuclear magnetic resonance metabolomics in cardiovascular epidemiology and genetics. , 2015, Circulation. Cardiovascular genetics.

[20]  M. Mayr,et al.  Lipidomics: Quest for Molecular Lipid Biomarkers in Cardiovascular Disease , 2014, Circulation. Cardiovascular genetics.

[21]  F. Kronenberg,et al.  Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck Study. , 2014, Journal of the American College of Cardiology.

[22]  T. Spector,et al.  Lipidomics Profiling and Risk of Cardiovascular Disease in the Prospective Population-Based Bruneck Study , 2014, Circulation.

[23]  Xiang Wang,et al.  Cholesterol Levels and Risk of Hemorrhagic Stroke: A Systematic Review and Meta-Analysis , 2013, Stroke.

[24]  J. Spence.  Statins do not cause intracerebral hemorrhage , 2012, Neurology.

[25]  S. Carr,et al.  Lipid profiling identifies a triacylglycerol signature of insulin resistance and improves diabetes prediction in humans. , 2011, The Journal of clinical investigation.

[26]  J. Danesh,et al.  Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies , 2010, The Lancet.

[27]  J. Danesh,et al.  Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. , 2009, JAMA.

[28]  M. Endres,et al.  Statin Treatment in Patients With Intracerebral Hemorrhage , 2018, Stroke.

[29]  F. Chen,et al.  Effects of Anacetrapib in Patients With Atherosclerotic Vascular Disease , 2018 .

[30]  R. Califf,et al.  Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. , 2015, The New England journal of medicine.

[31]  XiangWang,et al.  Cholesterol Levels and Risk of Hemorrhagic Stroke , 2013 .